ClinicalTrials.gg
CompletedNCT02435316PBSUpdated Mar 29, 2023

Comparison of Educational Methods for Teaching Peripheral Blood Smears

An interventional study of Case vignette-based teaching of cell recognition and Compare-contrast basic science teaching of cell recognition in Hematologic Diseases, sponsored by The Reading Hospital and Medical Center. Completed at 1 site in United States. Open to participants aged 26 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by The Reading Hospital and Medical Center · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
26 Years to 40 Years
Sex
All
01

Study summary

This is a prospective, randomized controlled, crossover trial comparing the effectiveness one two curricular designs to teaching peripheral blood smears to residents.

Read the detailed description

General Approach:

This study will employ a randomized, controlled design and will use as its outcomes two separate post-tests, one after the first teaching session and one 4 weeks after the second intervention.

Design The investigators are attempting to find whether the combination of basic science education using an 1-hour additive microskills- building method along with compare/ contrast model versus a 1-hour traditional case-based format would improve performance on a visual recognition test of hematology questions. A final test at 4 weeks after the cross-over between the two groups will also help investigators analyze whether the order of exposure to the teaching method would have an impact on the final performance.

Sampling, including sample size and statistical power:

Sample size will be between 40-50 resident physicians meeting inclusion criteria for the study. There is not enough data in the literature to effectively determine power, so we will use a convenience sample of the largest feasible group (around 40).

Collection of data:

Data will be collected on an excel spreadsheet and will be permanently de-identified on that spreadsheet; it will be kept on a password-protected site.

Information management and analysis software:

Data will be entered into a password protected excel spreadsheet and each study participant will be assigned a unique identifier code which will be used to link the data. Statistical analysis will be performed using SPSS version 20.

Data entry, editing and management, including handling of data collection forms, different versions of data, and data storage and disposition:

Paper surveys and tests will be collected, recorded and locked; they will be destroyed 2 years after termination of the study. A paired t-test will be used to compare the two samples means for significance.

Quality Control / Assurance:

Pretest and post-tests will be checked against a gold standard, a hospital board-certified hematopathologist, to check the quality of the slides.

Bias in data collection, measurement and analysis:

Given the small numbers of participants expected, a Type 1 error (failure to detect a difference in groups when one exists) is possible, as the study will possibly be underpowered.

02

Conditions studied

  • Hematologic Diseases

Browse trials for

Keywords

  • Education
03

In context

Hematologic Diseases

609 studies on the registry are indexed under Hematologic Diseases; 108 are open to participants now.

This study's enrollment of 30 is below the median of 50 across 410 interventional studies indexed under Hematologic Diseases.

Browse Hematologic Diseases studies →

Lead sponsor

The Reading Hospital and Medical Center is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
26 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Internal medicine and Family Medicine residents and faculty at The Reading Hospital and Medical Center having completed medical school

Exclusion criteria

Exclusion Criteria:

  • Practicing/ board certified hematologists
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Group 1

    Group 1 will receive 1 hour of compare-contrast basic science teaching of cell recognition to enhance recognition of those photographs, followed by 1 hour Case vignette-based teaching of cell recognition 2 weeks later

    Other: Case vignette-based teaching of cell recognition · Other: Compare-contrast basic science teaching of cell recognition

  • Active comparator
    Group 2

    Group 2 will receive 1 hour of Case vignette-based teaching of cell recognition followed by compare-contrast basic science teaching of cell recognition 2 weeks later

    Other: Case vignette-based teaching of cell recognition · Other: Compare-contrast basic science teaching of cell recognition

Interventions

  • OtherCase vignette-based teaching of cell recognition

    Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.

  • OtherCompare-contrast basic science teaching of cell recognition

    The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.

06

What researchers measure

Primary outcomes

  1. Improvement in post test scores at 2 and 4 weeks after education

    Primary outcome was an improvement in test score from pre-test to 2 and 4-week post-test. All participants took a 15-question pretest in addition to a posttest at 2 and 4 weeks. Each test consisted of pictures of various cell types from the peripheral blood.

    Time frame: 4 weeks

07

Study locations

1 site
  • Reading Health System
    West Reading, Pennsylvania 19612, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jun 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2015
First posted
May 6, 2015
Start
Apr 2012
Primary completionActual
Jun 2012
CompletionActual
Feb 12, 2013
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02435316
Lead sponsor
The Reading Hospital and Medical Center
Responsible party
Anthony A. Donato (Associate Program Director, Inpatient Medicine, The Reading Hospital and Medical Center) — Principal investigator
First posted
May 6, 2015
Start date
Apr 2012
Primary completion
Jun 2012
Completion
Feb 12, 2013
Last update
Mar 29, 2023

Study contacts

Anthony Donato, MD
study director · The Reading Hospital and Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion